These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16218879)

  • 1. Potential role for immunomodulatory therapy in atherosclerotic plaque stabilisation.
    Aukrust P; Yndestad A; Smith C; Sandberg WJ; Ueland T; Waehre T; Halvorsen B; Gullestad L; Damås JK
    Expert Opin Pharmacother; 2005 Oct; 6(13):2169-80. PubMed ID: 16218879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation in coronary artery disease: potential role for immunomodulatory therapy.
    Aukrust P; Yndestad A; Waehre T; Gullestad L; Halvorsen B; Damås JK
    Expert Rev Cardiovasc Ther; 2005 Nov; 3(6):1111-24. PubMed ID: 16293001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases.
    Schieffer B; Drexler H
    Am J Cardiol; 2003 Jun; 91(12A):12H-18H. PubMed ID: 12818730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes.
    Monroe VS; Kerensky RA; Rivera E; Smith KM; Pepine CJ
    J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):23S-30S. PubMed ID: 12644337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins.
    Kwak BR; Mulhaupt F; Mach F
    Autoimmun Rev; 2003 Oct; 2(6):332-8. PubMed ID: 14550874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and molecular mechanisms of statins: an update on pleiotropic effects.
    Satoh M; Takahashi Y; Tabuchi T; Minami Y; Tamada M; Takahashi K; Itoh T; Morino Y; Nakamura M
    Clin Sci (Lond); 2015 Jul; 129(2):93-105. PubMed ID: 25927679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?
    McCarey DW; Sattar N; McInnes IB
    Arthritis Res Ther; 2005; 7(2):55-61. PubMed ID: 15743490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward immunomodulatory and anti-inflammatory properties of statins.
    Arnaud C; Braunersreuther V; Mach F
    Trends Cardiovasc Med; 2005 Aug; 15(6):202-6. PubMed ID: 16182129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of HMG-CoA reductase inhibitors in regulation of the inflammatory processes].
    Cecha J; Drabek G; Błazelonis A; Romanowski W; Zubelewicz-Szkodzińska B
    Wiad Lek; 2004; 57(5-6):255-8. PubMed ID: 15518071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plaque passivation: role of statins in acute coronary syndromes.
    Singh S; Bahl VK
    Indian Heart J; 2003; 55(6):605-10. PubMed ID: 14989509
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical value of drugs targeting inflammation for the management of coronary artery disease.
    Duchatelle V; Kritikou EA; Tardif JC
    Can J Cardiol; 2012; 28(6):678-86. PubMed ID: 22926034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque?
    Akdim F; van Leuven SI; Kastelein JJ; Stroes ES
    Curr Pharm Des; 2007; 13(10):1003-12. PubMed ID: 17430164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vulnerable plaque and inflammation: potential clinical strategies.
    Drakopoulou M; Toutouzas K; Michelongona A; Tousoulis D; Stefanadis C
    Curr Pharm Des; 2011 Dec; 17(37):4190-209. PubMed ID: 22204378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins.
    Smith C; Halvorsen B; Otterdal K; Waehre T; Yndestad A; Fevang B; Sandberg WJ; Breland UM; Frøland SS; Oie E; Gullestad L; Damås JK; Aukrust P
    Cardiovasc Res; 2008 Jul; 79(1):195-203. PubMed ID: 18339644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue factor and coronary artery disease.
    Moons AH; Levi M; Peters RJ
    Cardiovasc Res; 2002 Feb; 53(2):313-25. PubMed ID: 11827681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.
    Koh KK
    Cardiovasc Res; 2000 Sep; 47(4):648-57. PubMed ID: 10974215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Etiology of acute coronary syndrome--unstable plaque].
    Meyer BJ; Claeys D
    Ther Umsch; 2002 Feb; 59(2):61-5. PubMed ID: 11887550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin therapy: beyond cholesterol lowering and antiinflammatory effects.
    Yeung AC; Tsao P
    Circulation; 2002 Jun; 105(25):2937-8. PubMed ID: 12081982
    [No Abstract]   [Full Text] [Related]  

  • 20. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells.
    Schönbeck U; Gerdes N; Varo N; Reynolds RS; Horton DB; Bavendiek U; Robbie L; Ganz P; Kinlay S; Libby P
    Circulation; 2002 Dec; 106(23):2888-93. PubMed ID: 12460867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.